Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (PKAN) and methods for the synthesis of such compounds
The invention relates to (S)-acyl-4′-phosphopantetheine derivatives, methods of their synthesis, and related medical uses of such compounds. Preferred medical uses relate to the treatment of neurodegenerative diseases, such as PKAN.
1. A method of treating pantothenate kinase-associated neurodegeneration (PKAN), comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the structural formula:
wherein:
R 1 is —H, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR 11 , —C(O)OR 11 , —C(O)NR 11 R 12 , —C═NR 11 , —CN, —OR 11 , —OC(O)R 11 , —NR 11 R 12 , —NR 11 C(O)R 12 , —NO 2 , —N═CR 11 R 12 or -halogen;
R 2 and R 3 are independently selected from the group consisting of: —H, -methyl, -ethyl, -phenyl, acetoxymethyl (AM), pivaloyloxymethyl (POM),
R 2 and R 3 jointly form a structure selected from the group consisting of:
wherein
R 4 is —H or -alkyl;
R 5 is —H or -alkyl;
R 6 is —H, -alkyl, or —CH 2 (CO)OCH 3 ;
R 7 is —H, -alkyl or -halogen;
R 8 is —H or -alkyl;
R 9 is —H, -alkyl;
R 10 is —H, -alkyl;
R 11 and R 12 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, or halogen;
or a pharmaceutically acceptable salt or solvate thereof.
2. The method of claim 1 , wherein in the compound of structure I, R 2 and R 3 are each H.
3. The method of claim 1 , wherein in the compound of structure I, R 1 is methyl.
4. The method of claim 1 , wherein in the compound of structure I, R 1 is methyl, and R 2 and R 3 are each H.
5. The method of claim 1 , wherein the compound of structure I is a D stereoisomer.
6. The method of claim 1 , wherein the compound of structure I is a D stereoisomer, in which R 1 is methyl, and R 2 and R 3 are each H.
7. The method of claim 1 , wherein the pharmaceutically acceptable salt or solvate of the compound of structure I is a calcium salt.
8. The method of claim 1 , wherein the compound of structure I is a D stereoisomer, in which R 1 is methyl, and R 2 and R 3 are each H, and wherein the pharmaceutically acceptable salt or solvate thereof is a calcium salt.